Bone morphogenetic protein signalling is required for the anti-mitogenic effect of the proteasome inhibitor MG-132 on colon cancer cells. (Q39561199)
Jump to navigation
Jump to search
scientific article published on 14 April 2008
Language | Label | Description | Also known as |
---|---|---|---|
English | Bone morphogenetic protein signalling is required for the anti-mitogenic effect of the proteasome inhibitor MG-132 on colon cancer cells. |
scientific article published on 14 April 2008 |
Statements
Bone morphogenetic protein signalling is required for the anti-mitogenic effect of the proteasome inhibitor MG-132 on colon cancer cells (English)
W K K Wu
Y C Wu
Z J Li
L Yu
3 references
1 reference
1 reference
1 reference
1 reference
1 reference